Proacta Inc.
This article was originally published in Start Up
Executive Summary
Oncology drug developer Proacta Inc. is taking advantage of tumor hypoxia to activate a nontoxic prodrug to a cytotoxic chemotherapeutic. Since the agent acts only in areas of low oxygenation, it is nontoxic to normal tissues.
You may also be interested in...
New Zealand Biotech
The other land down under is getting serious about moving its affordable world-class science to global markets. For start-ups, establishing a US presence may be key. The three NZ start-ups that we profile in this issue--CoDa Therapeutics, Proacta and Protemix--have found their own paths for taking their technologies to the worldwide market via a US presence.
Start-Up Previews (07/2007)
A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Start-Ups in Obesity," "New Technologies for Infertility," and "New Zealand Biotech." Plus these Start-Ups Across Health Care: Intelect Medical, N Spine, and Solace Pharmaceuticals.
New Zealand Biotech
The other land down under is getting serious about moving its affordable world-class science to global markets. For start-ups, establishing a US presence may be key. The three NZ start-ups that we profile in this issue--CoDa Therapeutics, Proacta and Protemix--have found their own paths for taking their technologies to the worldwide market via a US presence.